Ofer Haviv
Chief Executive Officer bei EVOGENE LTD.
Vermögen: - $ am 31.03.2024
Profil
Ofer Haviv is currently the President & Chief Executive Officer at Evogene Ltd., Chairman at Evofuel Ltd., Chairman at Evogene, Inc., Chairman at Lavie Bio Ltd., and Chairman at Biomica Ltd.
He previously worked as the Treasurer & Finance Director at Compugen Ltd.
Mr. Haviv completed his undergraduate degree at Tel-Aviv University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
EVOGENE LTD
-.--% | 17.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Ofer Haviv
| Unternehmen | Position | Beginn |
|---|---|---|
| EVOGENE LTD. | Chief Executive Officer | 01.12.2004 |
| Evofuel Ltd. | Chairman | 01.01.2012 |
| Evogene, Inc. | Chairman | 01.01.2006 |
Biomica Ltd.
 Biomica Ltd. Miscellaneous Commercial ServicesCommercial Services Biomica Ltd. engages in the provision of biopharmaceutical services. Its technology focuses on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. The company was founded by Yehuda Ringel in 2017 and is headquartered in Rehovot, Israel. | Chairman | - |
| Lavie Bio Ltd. | Chairman | - |
Ehemalige bekannte Positionen von Ofer Haviv
| Unternehmen | Position | Ende |
|---|---|---|
| COMPUGEN LTD. | Director of Finance/CFO | - |
Ausbildung von Ofer Haviv
| Tel-Aviv University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| COMPUGEN LTD. | Health Technology |
| EVOGENE LTD. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
| Evofuel Ltd. | |
| Evogene, Inc. | |
| Lavie Bio Ltd. | |
Biomica Ltd.
Biomica Ltd. Miscellaneous Commercial ServicesCommercial Services Biomica Ltd. engages in the provision of biopharmaceutical services. Its technology focuses on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. The company was founded by Yehuda Ringel in 2017 and is headquartered in Rehovot, Israel. | Commercial Services |
